Chronic Kidney DiseasesFerritinNCT05947552
Serum Ferritin In CKD Patients Serum Ferritin
An observational study of Chronic Kidney Diseases, run by Assiut University at 1 site in Egypt.
Trial summary
Variability of serum ferritin in CKD patients and how these variables may affect the treatment decisions with iron supplements Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Chronic Kidney Diseases
- What is being tested?
- Serum ferritin
- How many people
- 55 participants
- Where
- 1 siteEgypt
- Study dates
- 8 Jul 2023to 11 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Adult
Study population: ALL CKD patients who are not dialysis Stage 3 to 5
Who may be able to join
- ALL CKD patients stage 3 to 5 not on dialysis
Who cannot join
- inflammatory chronic diseases IDA Autoimmune disorders Liver diseases Malignancy Infections
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Variability of Serum Ferritin in CKD Patients and How These Variables May Affect the Treatment Decisions With Iron
Variability of serum ferritin in CKD patients and how these variables may affect the treatment decisions with iron supplements
Read the detailed description
Serum ferritin has a wide range Variability in CKD patients this makes the use of serum ferritin as an indicator of iron deficiency is limited and mostly CKD is secondary to inflammation so serum ferritin as ferritin is an acute phase reactants so it will be very high in CKD patients ,
- Conditions
- Chronic Kidney Diseases
- Being tested
- Serum ferritin
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum ferritinDrug
Serum ferritin in CKD patients
| Study group | Role | What they receive |
|---|---|---|
| Chronic kidney disease Patients | Chronic kidney Disease Patients stage 3 to stage 5 Receives: Drug: Serum ferritin |
What is being measured
The primary outcome is the main question the study is designed to answer.
to assess the role of serum ferritin in CKD patients din in CKD patients and how these variability
affect treatment decisions with iron
Measured: Recurring
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2023
- Study start8 Jul 2023 (estimated)
- Primary completion11 Jan 2025 (estimated)
- Study completion11 Jan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseasesStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Reham Mahmoud Osman, Assiut University
- Investigators
- Hawaid Ab Nafady, Professor, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05947552
- Sponsor's protocol ID
- Serum Ferritin in CKD patients
- Acronym
- Ferritin
- Status last verified
- Jul 2023
- First submitted
- 23 May 2023
- Last updated
- 17 Jul 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Variability of Serum Ferritin in CKD Patients and How These Variables May Affect the Treatment Decisions With Iron
- ClinicalTrials.gov ID
- NCT05947552
- Acronym / sponsor ID
- Ferritin / Serum Ferritin in CKD patients
- Conditions
- Chronic Kidney Diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 8 Jul 2023 (estimated)
- Primary completion
- 11 Jan 2025 (estimated)
- Study completion
- 11 Jan 2025 (estimated)
- First posted
- 17 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Variability of serum ferritin in CKD patients and how these variables may affect the treatment decisions with iron supplements
Detailed description
Serum ferritin has a wide range Variability in CKD patients this makes the use of serum ferritin as an indicator of iron deficiency is limited and mostly CKD is secondary to inflammation so serum ferritin as ferritin is an acute phase reactants so it will be very high in CKD patients ,
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chronic kidney disease Patients | – | Drug: Serum ferritinChronic kidney Disease Patients stage 3 to stage 5 |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Age groups
- Adult
- Study population
- ALL CKD patients who are not dialysis Stage 3 to 5
Key inclusion criteria (1 listed)
- ALL CKD patients stage 3 to 5 not on dialysis
Key exclusion criteria (1 listed)
- inflammatory chronic diseases IDA Autoimmune disorders Liver diseases Malignancy Infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serum ferritinSerum ferritin in CKD patients | Drug | Chronic kidney disease Patients |
Primary outcome
to assess the role of serum ferritin in CKD patients din in CKD patients and how these variability
Time frame: Recurring
affect treatment decisions with iron
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2023.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Diseases
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hawaid Ab Nafady, Professor study director
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Diseases, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Reham Ma Osman, doctor (01065934817, rehamaskary1234@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
to assess the role of serum ferritin in CKD patients din in CKD patients and how these variability (time frame: Recurring). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2023; AzTrials last refreshed its copy on 6 Nov 2026.